NASDAQ:BCYC

Bicycle Therapeutics - BCYC Stock Forecast, Price & News

$22.40

+2.23 (+11.06%)

(As of 03/28/2023 05:12 PM ET)

Add

Compare

Today's Range: $20.78
▼
$22.59
50-Day Range: $20.02
▼
$28.94
52-Week Range: $12.08
▼
$50.47

Volume: 520,009 shs
Average Volume: 315,466 shs
Market Capitalization: $477.34 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $51.36

Institutional Ownership

Bicycle Therapeutics MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.85 Rating Score
Upside/Downside: 129.4% Upside
$51.36 Price Target
Short Interest: Bearish
14.31% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.36
Based on 2 Articles This Week
Insider Trading: Selling Shares
$279,441 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($4.72) to ($5.06) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.68 out of 5 stars

Medical Sector

866th out of 1,002 stocks

Pharmaceutical Preparations Industry

420th out of 488 stocks

3.4

Analyst's Opinion

Consensus Rating
Bicycle Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.85, and is based on 11 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $51.36, Bicycle Therapeutics has a forecasted upside of 129.4% from its current price of $22.39.
Amount of Analyst Coverage
Bicycle Therapeutics has only been the subject of 4 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
14.31% of the outstanding shares of Bicycle Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Bicycle Therapeutics has a short interest ratio ("days to cover") of 10.3, which indicates bearish sentiment.
Change versus previous month
Short interest in Bicycle Therapeutics has recently decreased by 2.87%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Bicycle Therapeutics does not currently pay a dividend.
Dividend Growth
Bicycle Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BCYC.

1.3

News and Social Media Coverage

News Sentiment
Bicycle Therapeutics has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Bicycle Therapeutics this week, compared to 6 articles on an average week.
Search Interest
Only 2 people have searched for BCYC on MarketBeat in the last 30 days. This is a decrease of -82% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Bicycle Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Bicycle Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $279,441.00 in company stock.
Percentage Held by Insiders
Only 9.00% of the stock of Bicycle Therapeutics is held by insiders.
Percentage Held by Institutions
77.88% of the stock of Bicycle Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Bicycle Therapeutics are expected to decrease in the coming year, from ($4.72) to ($5.06) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Bicycle Therapeutics is -5.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Bicycle Therapeutics is -5.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Bicycle Therapeutics has a P/B Ratio of 2.46. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Bicycle Therapeutics (NASDAQ:BCYC) Stock

Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom.

Receive BCYC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bicycle Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BCYC Stock News Headlines

March 26, 2023 | americanbankingnews.com

Analysts Set Bicycle Therapeutics plc (NASDAQ:BCYC) Price Target at $51.36

March 18, 2023 | msn.com

Bicycle ridership in Portland has dropped off significantly over past 6 years, PBOT says

March 28, 2023 | Investor Place Media (Ad)

The "King Of Quants" sees 10X potential...

Eric Fry believes he just discovered America's next "Wealth Supercluster" and it's forming in the place you'd least expect. Investors are already flocking there for a chance at 1,000%+ returns. Here's how you could join them before it's too late...

March 1, 2023 | msn.com

Fuller Center Bicycle Adventure pedals hope to end poverty housing

March 1, 2023 | markets.businessinsider.com

What 8 Analyst Ratings Have To Say About Bicycle Therapeutics

February 28, 2023 | msn.com

We are fighting war of attrition with rip-off rivals, says Brompton Bicycle boss

February 28, 2023 | forbes.com

Electric Bike Battery Collection And Recycling Program Started By U.K.’s Bicycle Association

February 28, 2023 | msn.com

Bicycle Therapeutics GAAP EPS of -$1.01 beats by $0.05, revenue of $3.19M misses by $0.56M

March 28, 2023 | Weiss Ratings (Ad)

Urgent Warning

This was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …

February 28, 2023 | finance.yahoo.com

Bicycle Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

February 17, 2023 | finance.yahoo.com

Bicycle Therapeutics- Solid Cancer Drug Data Reinforces Investment Case

February 15, 2023 | marketwatch.com

Bicycle Therapeutics Upbeat on Early BT8009 Study Results >BCYC

February 15, 2023 | marketwatch.com

E-Bicycle Motors Market Analysis Report 2023 Along with Statistics Figures, Forecasts till 2028

February 15, 2023 | marketwatch.com

Recumbent Bicycle Market Management of Massive Data and Availability to Hamper the Industry Growth

February 14, 2023 | marketwatch.com

Bicycle Tire Market 2023-2027: Climbs on Positive Latest Outlook of Booming Sales | 133 Pages Research

February 14, 2023 | finance.yahoo.com

Bicycle Therapeutics Announces Phase I Dose Escalation Results from Ongoing Phase I/II Study of BT8009

February 13, 2023 | marketwatch.com

Bicycle and Components Market 2023-2025 | Achieving Sustainable Growth: Strategies & Tips | 107 Pages Report

February 11, 2023 | marketwatch.com

Bicycle Trailers Market With Massive Data and Availability to Hamper the Industry Growth | 115 Pages Report

February 10, 2023 | marketwatch.com

Bicycle Modification Parts Market is expected to witness Incredible Growth during 2023-2028

February 10, 2023 | marketwatch.com

Bicycle Accessories Market Opportunity, Size, Share, Growth, Segmentation, In-depth Analysis Research Report 2023-2028

February 10, 2023 | marketwatch.com

Bicycle Infotainment System Market 2023 Structure Along With Size, Trends, Revenue, Market segments, Forecast to 2029

February 10, 2023 | marketwatch.com

Bicycle Carbon Frames Market Size 2023 With End-user Industries, Segments Covered in the Report

February 9, 2023 | marketwatch.com

Bicycle Brake Fluid Market [2023-2028] | Latest Study on Industry Trends & Forecast with Top Countries Data

February 9, 2023 | marketwatch.com

Electric Bicycle Mid-drive Motor Market Global Demand, Opportunities, Trends, Analysis and Forecast to 2028

February 9, 2023 | marketwatch.com

Bicycle Tubeless Tire Market Report Covers Latest Market Trends, Drivers & Restraints, Key Players, Strategies And R&D Investments Upto 2028

February 8, 2023 | marketwatch.com

Shared Bicycle Service Market Size with Global Industry Analysis, Revenue, Future Growth, Business Prospects and Forecast 2023 to 2029

February 8, 2023 | marketwatch.com

Bicycle Crankset Markets Industry Analysis Database for Period from 2023-2026

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive BCYC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bicycle Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BCYC Company Calendar

Last Earnings: 11/03/2021
Today: 3/28/2023
Next Earnings (Estimated): 5/04/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:BCYC
CUSIP: N/A
CIK: 1761612
Web: www.bicycletherapeutics.com
Phone: 441223261503
Fax: N/A
Employees: 119
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $51.36
High Stock Price Forecast: $74.00
Low Stock Price Forecast: $30.00
Forecasted Upside/Downside: +136.5%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.85
Research Coverage: 13 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.80)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-112,720,000.00
Net Margins: -779.35%
Pretax Margin: -789.89%
Return on Equity: -37.51%
Return on Assets: -26.02%

Debt

Debt-to-Equity Ratio: 0.11
Current Ratio: 6.92
Quick Ratio: 6.92

Sales & Book Value

Annual Sales: $14.46 million
Price / Sales: 32.01
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $9.12 per share
Price / Book: 2.38

Miscellaneous

Outstanding Shares: 21,310,000
Free Float: 19,388,000
Market Cap: $462.85 million
Optionable: Not Optionable
Beta: 0.77

Key Executives

Kevin Lee
Chief Executive Officer & Executive Director

Lee H. Kalowski
President & Chief Financial Officer

Alistair Milnes
Chief Operating Officer

Michael Skynner
Chief Technology Officer

Nicholas Keen
Chief Scientific Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

BCYC Stock - Frequently Asked Questions

Should I buy or sell Bicycle Therapeutics stock right now?: 13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bicycle Therapeutics in the last year. There are currently 2 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BCYC shares.
View BCYC analyst ratings or view top-rated stocks.
What is Bicycle Therapeutics' stock price forecast for 2023?: 13 brokerages have issued 1 year price targets for Bicycle Therapeutics' shares. Their BCYC share price forecasts range from $30.00 to $74.00. On average, they expect the company's stock price to reach $51.36 in the next twelve months. This suggests a possible upside of 136.5% from the stock's current price.
View analysts price targets for BCYC or view top-rated stocks among Wall Street analysts.
How have BCYC shares performed in 2023?: Bicycle Therapeutics' stock was trading at $29.60 at the start of the year. Since then, BCYC stock has decreased by 26.6% and is now trading at $21.72.
View the best growth stocks for 2023 here.
When is Bicycle Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our BCYC earnings forecast.
How were Bicycle Therapeutics' earnings last quarter?: Bicycle Therapeutics plc (NASDAQ:BCYC) posted its quarterly earnings data on Wednesday, November, 3rd. The company reported ($0.59) EPS for the quarter, topping analysts' consensus estimates of ($0.61) by $0.02. The firm had revenue of $4.33 million for the quarter, compared to analyst estimates of $5.29 million. Bicycle Therapeutics had a negative net margin of 779.35% and a negative trailing twelve-month return on equity of 37.51%.
What ETFs hold Bicycle Therapeutics' stock?: ETFs with the largest weight of Bicycle Therapeutics (NASDAQ:BCYC) stock in their portfolio include Loncar Cancer Immunotherapy ETF (CNCR), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Harbor Disruptive Innovation ETF (INNO), Harbor Health Care ETF (MEDI), First Trust IPOX Europe Equity Opportunities ETF (FPXE), iShares Biotechnology ETF (IBB), Invesco Nasdaq Biotechnology ETF (IBBQ).ProShares Ultra Nasdaq Biotechnology (BIB).
What other stocks do shareholders of Bicycle Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Bicycle Therapeutics investors own include Aldeyra Therapeutics (ALDX), AVEO Pharmaceuticals (AVEO), Fulcrum Therapeutics (FULC), Mersana Therapeutics (MRSN), AbbVie (ABBV), Adverum Biotechnologies (ADVM), Agenus (AGEN), Applied Genetic Technologies (AGTC), Akero Therapeutics (AKRO) and Alector (ALEC).

When did Bicycle Therapeutics IPO?: (BCYC) raised $64 million in an initial public offering (IPO) on Thursday, May 23rd 2019. The company issued 4,300,000 shares at $14.00-$16.00 per share. Goldman Sachs, Jefferies and Piper Jaffray served as the underwriters for the IPO and Canaccord Genuity was co-manager.
What is Bicycle Therapeutics' stock symbol?: Bicycle Therapeutics trades on the NASDAQ under the ticker symbol "BCYC."
Who are Bicycle Therapeutics' major shareholders?: Bicycle Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Point72 Asset Management L.P. (3.40%), Morgan Stanley (2.43%), First Light Asset Management LLC (2.35%), Verition Fund Management LLC (1.28%), Price T Rowe Associates Inc. MD (1.14%) and Soleus Capital Management L.P. (0.87%). Insiders that own company stock include Kate Bingham, Kevin Lee, Lee Kalowski, Nicholas Keen, Nigel Crockett, Pierre Legault, Plc Glaxosmithkline and Stephen B Alexander.
View institutional ownership trends.
How do I buy shares of Bicycle Therapeutics?: Shares of BCYC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Bicycle Therapeutics' stock price today?: One share of BCYC stock can currently be purchased for approximately $21.72.
How much money does Bicycle Therapeutics make?: Bicycle Therapeutics (NASDAQ:BCYC) has a market capitalization of $462.85 million and generates $14.46 million in revenue each year. The company earns $-112,720,000.00 in net income (profit) each year or ($3.80) on an earnings per share basis.
How many employees does Bicycle Therapeutics have?: The company employs 119 workers across the globe.
How can I contact Bicycle Therapeutics?: Bicycle Therapeutics' mailing address is B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0, CB22 3AT. The official website for the company is www.bicycletherapeutics.com. The company can be reached via phone at 441223261503 or via email at david.borah@bicycletx.com.

This page (NASDAQ:BCYC) was last updated on 3/28/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Bicycle Therapeutics - BCYC Stock Forecast, Price & News

Bicycle Therapeutics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Bicycle Therapeutics (NASDAQ:BCYC) Stock

BCYC Stock News Headlines

BCYC Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

BCYC Stock - Frequently Asked Questions

Overall MarketRank^™